The identification of TNFR5 as a therapeutic target in diabetes by Turner, MD
The identification of TNFR5 as a therapeutic target in diabetes 
Running title:  Anti-TNFR5 diabetes strategies 
 
 
Mark D. Turner* 
Interdisciplinary Biomedical Research Centre, School of Science and Technology, 
Nottingham Trent University, Clifton Lane, Nottingham, NG11 8NS, United Kingdom. 
 
 
 
*Corresponding author: Dr. Mark D. Turner 
Tel: +44 115 848-3113 
E-mail: mark.turner@ntu.ac.uk  
 
 
 
 
 
 
 
 
 
 
Keywords: Biologics, diabetogenesis, islet cell death, phage display 
Abbreviations 
CD40 – cluster of differentiation 40 
CDR – complementarity determining region 
Fab – fragment, antibody-binding region 
Fc – fragment, crystallisable region 
Fv –fragment, variable region 
scFv – single chain variable region fragment 
IgG – immunoglobulin G 
NF-κB – nuclear factor kappa B 
STAT1 – signal transducer and activator of transcription 1 
T2D - type 2 diabetes 
TNFR5 – tumour necrosis factor receptor 5 
 
 
 
 
 
 
 
 
 
 
 
1. Type 2 diabetes: pancreatic β-cell dysfunction due to glucolipotoxicity  
Latest global estimates indicate that there are over 422 million adults currently living 
with diabetes (http://www.who.int/diabetes/global-report/en), of whichover 90% have 
type 2 diabetes (T2D).  Furthermore, numbers continue to rise at an alarming rate, with 
the current figure almost four times the number reported back in 1980. This represents a 
staggering rise in prevalence from 4.7% to 8.5% of the adult population. With diabetes 
complications including heart attack, stroke, kidney failure, leg amputation, blindness, 
and nerve damage, the disease is a major global health challenge, both to individuals and 
their families, and to national economies. Given that current oral and injectable treatment 
options also often become less effective over time, there is therefore an urgent need both 
to better understand the causes of the disease, and to identify new targets for therapeutic 
intervention.  
 
Along with failure of pancreatic β-cells to hypersecrete insulin in the face of ongoing 
insulin resistance, pancreatic β-cell death is a key component of T2D [1,2].   Obesity is a 
known causal link to the development of diabetes, and it is recognised that 
hyperglycaemia and hyperlipidaemia together contribute to drive glucolipotoxic loss of 
insulin-producing pancreatic β-cell mass. Obesity is also associated with increased 
visceral fat and central adiposity, Interestingly, whilst once thought to be cells whose 
only function was to serve as a general fat repository, it is now known that adipocytes 
play an important role in the release of pro-inflammatory cytokines that contribute to the 
pathogenesis of T2D [3].  
 
With specific regard to the pancreas, detailed mechanistic understanding of precisely how 
glucolipotoxicity drives pancreatic β-cell death has until recently proven the subject of 
much debate. Crucially however, new findings [4] indicate that it is pancreatic 
upregulation of the TNF receptor superfamily member, TNFR5 (also known as CD40), 
that leads to activation of the transcription factors NF-κB and STAT1 that drive islet 
inflammation that ultimately induces β-cell death [5-7]. Furthermore, inhibition of 
TNFR5 signalling though selective RNA interference abrogates glucolipotoxic induction 
of NF-κB and STAT1 activation [4]. These findings have major therapeutic implications, 
as clinical intervention strategies that target TNFR5 could potentially preserve functional 
β-cell mass in patients with T2D.  This in turn would slow down the progression of 
diabetes, and extend the period in which drugs such as sulphonylureas (that enhance 
insulin secretion) remain effective.  This would also delay the onset of diabetes 
complications, thereby improving the quality of life, and potentially extending the 
lifespan, of affected individuals.   
 
2. Expert Opinion 
TNFR5 is a type 1 transmembrane glycoprotein with a molecular mass of 48 kDa. It is 
also a member of the wider tumour necrosis factor receptor superfamily of death 
receptors. The identification of TNFR5 as the trigger that initiates islet cell death [4] 
opens the way for the development of a new class of diabetes therapeutic agents based 
upon TNFR5 antagonism. It should however be noted that antagonistic TNFR5 sinalling 
strategies have previously been employed to aid immunosuppression following 
transplantation, and also to treat people suffering from lupus and several types of cancer. 
Intervention has not always met with success though, and there are a number of reports 
where monoclonal antibodies targeted against the receptor ligand, CD40L, induced 
thromboembolic events [8-11]. Importantly, no such side-effects have been reported 
when the receptor itself, rather than ligand, was targeted. This fact notwithstanding, there 
are nevertheless still a number of potential pitfalls that could potentially arise through the 
use of full length anti-TMFR5 antibodies as T2D therapeutic agents. However, there are a 
number of molecular strategies that can be adopted to circumvent these dangers. These 
strategies are discussed below. 
 
2.1 Drug Repurposing 
In light of the aforementioned recent findings [4], existing antagonistic anti-TNFR5 
antibodies would at first appear to offer promising potential for the treatment of diabetes. 
However the unmodified antibody structure carries with it potentially dangerous 
consequences if used to treat diabetes. Specifically, while TNFR5 would bind to the 
complementarity determining regions (CDRs) located between the variable region heavy 
and light chain domains of the Fab portion of the IgG structure (Fig. 1), the Fc region of 
the antibody poses a problem. In particular the possibility exists that following TNFR5 
binding at the cell surface of β-cells, the Fc portion of the molecule might then bind to 
and activate immune cells. Should this occur there would be potentially catastrophic 
consequences for the pancreas, as this could for example trigger cell-mediated 
cytotoxicity through degranulation of natural killer cells, phagocytic opsonization of β-
cells by neurophils, or trigger immune cell production and release of reactive oxygen 
species that could also induce β-cell death. An alternative approach is therefore required. 
 2.2 Enzymatic Antibody Remodelling 
The simplest and least costly strategy to generate new therapeutic tools would be to start 
with well characterised antagonistic TNFR5 antibodies, then remove the Fc region 
through use of enzymatic IgG cleavage sites first demonstrated more than half a century 
ago using either papain [12] or pepsin [13]. Pepsin cleavage (Fig. 1a, yellow arrows) 
would generate one bivalent anti-TNFR5 F(ab’)2 molecule, which if required could then 
be further processed through addition of disuphide reducing agent to generate two 
monovalent Fab molecules. Papain cleavage (Fig 1b, light blue arrows) by contrast would 
directly result in the generation of two monovalent Fab molecules. In both cases removal 
of the Fc portion of the antibody would produce antibody fragments still capable of 
antagonizing TNFR5 signalling, but with the Fc portion of the original antibody molecule 
no longer present the remaining fragments would not now be able to promote 
agglutination, precipitation, opsonization, or cell lysis.  
 
2.3 Phage Display 
Phage display was first documented in 1985, molecular biology strategies being 
employed to generate peptides fused to bacteriophage coat protein III [14]. This 
technique was subsequently refined for display and selection of human antibodies on 
phage [15]. Further technological advances mean that it is now possible to use phage 
display to generate soluble F(ab’)2 or Fab molecules, or the smaller scFv or Fv variable 
region fragments (Fig. 2). The use of phage display to construct scFv fragments has in 
particular proven to be highly successful, both for diagnostic and therapeutic applications.   
 A key consideration when designing scFv constructs is the need to allow sufficient steric 
flexibility for the CDR to form between the respective variable heavy and light chain 
domains. This necessitates incorporating a linker region (shown in red, Fig. 2b lower left 
hand panel) that is suitably flexible. As a consequence the linker region is typically rich 
in glycine and approximately 15 amino acids long [16]. However if the linker region 
were to be reduced to 5 amino acids, then the two variable domains would no longer be 
able to fold together. Instead adjacent scFvs would likely dimerize to form diabodies. 
This could significantly reduce the antigen dissociation constant, thereby leading to an 
increased antibody affinity of as much as 40-fold [17]. Were such an approach adopted to 
produce an anti-TNFR5 diabody, this could result in a drug able to be dosed at a much 
lower concentrations than therapeutic antibody fragments generated through either 
enzymatic cleavage or conventional scFv phage display strategies. Moreover, were still 
shorter linkers employed (one or two amino acids), then this would likely lead to the 
formation of triabodies or tetrabodies of even higher affinity for TNFR5.  
 
In conclusion there is still some way to go in the development of this new class of 
therapeutic drug but, based on the latest developments [4], neutralization of TNFR5 
should prevent, or at least delay, islet cell death that is driven by glucolipotoxicity. Anti-
TNFR5 biologics are likely to prove the most effective way to achieve this goal. Only 
once these novel candidate molecules have been generated though will we be able to 
assess each for efficacy and potential toxicity. The challenge now is for academia and 
industry to come together to successfully develop such drugs, and by so doing help 
address the currently unmet clinical need to find effective new diabetes treatments.  
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Figure Legends 
 
Figure 1. Enzymatic generation of anti-TNFR5 antibody fragments. Utilising 
existing known antagonistic anti-TNFR5 antibodies it is possible to separate the TNFR5-
binding complementarity determining regions located between the variable heavy chain 
(light green) and light chain (brown) domains of the IgG structure, from the immune cell-
interacting Fc portion of the antibody. This can be accomplished using either, a) papain 
(yellow arrow), or b) pepsin (light blue arrow). This generates either bivalent F(ab’)2, or 
monovalent Fab antagonistic anti-TNFR5 antibody fragments.   
 
 
Figure 2. Phage display generation of anti-TNFR5 antibody fragments. Utilising 
phage display technology it is possible to generate a number of different possible 
antibody fragments, including bivalent F(ab’)2, or monovalent Fab, scFv, or Fv domains. 
This could be accomplished for TNFR5 by amplifying the immunoglobulin heavy and 
light chain region genes using PCR technology, ligating with a linker region where 
necessary, then subcloning into a phagemid vector to generate a recombinant phage 
capable of expressing the desired antibody fragment.  
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